GRP and neoplasm: In addition to these clinically investigated peptides, research has identified non-coding RNA-derived micropeptides, gastrin-releasing peptide (GRP) and its precursor pro-GRP, and tumor-homing peptides such as iRGD, angiopep2, and PL3, which target tumor-specific receptors and microenvironment components.